Goldman Sachs SELL

Otsuka HD (4578)

Jul 26, 20268 pages页

From the report报告摘录FDA Approval Catalyst: US FDA approves Simtriyo (centanafadine) for ADHD as first NDSRI; critical success hinges on balancing efficacy/safety amid suicidal risk and abuse potential warnings, plus DEA scheduling…

Read the full report + PDF阅读全文与 PDF

The full summary (5 key points) and the original Goldman Sachs PDF are for MastermindX Pro members. 完整摘要（5 个要点）与 Goldman Sachs 原始 PDF 为 MastermindX Pro 会员专享。

Read on MastermindX前往 MastermindX 阅读

Related institutional research相关机构研报

Not investment advice. MastermindX hosts third-party institutional research for reference and education; ratings and views are the authors', not ours. Browse the full Research Vault → 非投资建议。MastermindX 仅收录第三方机构研究，供参考与学习；其中评级与观点均属作者本人。浏览完整研报库 →